Richard Smith, MD
Psychiatry · Roswell, NMNPI 1225107824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,098, 2.9 times the $373 reported in 2019. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $14.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$731
- Teva Pharmaceuticals USA, Inc.$543
- Otsuka America Pharmaceutical, Inc.$510
- AbbVie$498
- Sunovion Pharmaceuticals Inc.$218
- Neurocrine Biosciences, Inc.$170
- plus $576 from 10 others
What the payments were for
- Food & beverage$3,19198%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $731 |
| Teva Pharmaceuticals USA, Inc. | 37 | $543 |
| Otsuka America Pharmaceutical, Inc. | 30 | $510 |
| AbbVie(2 entities) | 31 | $498 |
| Sunovion Pharmaceuticals Inc. | 15 | $218 |
| Neurocrine Biosciences, Inc. | 8 | $170 |
| Johnson & Johnson | 10 | $155 |
| Alkermes, Inc. | 8 | $139 |
| E.r. Squibb & Sons, L.L.C. | 4 | $84 |
| Lundbeck LLC | 3 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Braeburn Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $12 |
How this compares
$3,245 in reported general payments places this provider in the 90th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $138,826 |
| AristadaAripiprazole Lauroxil | 34 | $95,998 |
| IngrezzaValbenazine Tosylate | 11 | $95,252 |
| Invega SustennaPaliperidone Palmitate | 13 | $33,689 |
| VraylarCariprazine Hcl | 19 | $30,241 |
| RexultiBrexpiprazole | 21 | $29,414 |
| TrintellixVortioxetine Hydrobromide | 28 | $18,560 |
| Lurasidone Hcl | 24 | $16,579 |
| Bupropion XlBupropion Hcl | 208 | $8,682 |
| Aripiprazole | 135 | $6,572 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 49 | $5,645 |
| Quetiapine Fumarate | 108 | $4,180 |
| Clonazepam | 275 | $3,182 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 70 | $2,992 |
| Buprenorphine Hcl | 15 | $2,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $543 | $138,82611 claims |
| Alkermes, Inc.Aristada | $139 | $95,99834 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $170 | $95,25211 claims |
| Johnson & JohnsonInvega Sustenna | $155 | $33,68913 claims |
| AbbVieVraylar | $498 | $30,24119 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $510 | $29,41421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $21 | $18,56028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 174 psychiatry providers in New Mexico.
Other psychiatry in Roswell
- Lynnet BulamboRoswell$2K
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Jefferson DavisSanta Fe$53K
- Ernest FloresLas Cruces$25K
- Yvonne HallRio Rancho$11K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.